Healthcare
With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.
Contact advisor
Banook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn moreKKR to invest in Precipart Group Ltd.
Kohlberg Kravis Roberts (KKR) has agreed to make a significant strategic investment in Precipart Group Ltd., a leading contract manufacturer of precision components for the medical device and aerospace industries. KKR plans to support the company in its continued growth organically and through M&A.
Learn moreTDK Corporation has divested its medical business HTI Medical to GTCR-backed Resonetics
Hutchinson Technology, Inc., a subsidiary of TDK Corporation, has sold its medical business HTI Medical to Resonetics, a portfolio company of GTCR.
Learn more
Jan De Backer
CEO, Fluidda NV
Read more
Celebrity-backed rehab center joins UK’s expanding addiction treatment network
DEAL FLASH: The Providence Projects, one of the UK’s leading providers of affordable private alcohol and drug rehabilitation services, has been acquired by UKAT Group, a network of rehabilitation clinics across the UK.
Learn more
Talk to our local specialist
Michael Goldman
Oaklins TM Capital